Puma Biotechnology Inc (PBYI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.50 (-0.21%), Market cap $0.36B, P/E ratio 14.69, 52-week low–high $3.07 ~ $7.80.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distri
Financial statements, price targets, institutional (13F) holdings and related news for Puma Biotechnology Inc are updated in real time on BlackAll Trade.
Puma Biotechnology Inc trades at $9.50 (-0.21%). Real-time quotes and charts are available on BlackAll Trade.
Puma Biotechnology Inc has a market cap of about $0.36B. Its P/E ratio is 14.69.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX,